Live Attenuated Zoster Vaccine Boosts Varicella Zoster Virus (VZV)-Specific Humoral Responses Systemically and at the Cervicovaginal Mucosa of Kenyan VZV-Seropositive Women

Catia T Perciani, Manmeet Sekhon, Sabrina Hundal, Bashir Farah, Mario A Ostrowski, A Omu Anzala, Lyle R McKinnon, Walter Jaoko, Kelly S MacDonald, Institute of Tropical and Infectious Diseases (UNITID) Group and the Kenyan AIDS Vaccine Initiative–Institute of Clinical Research (KAVI-ICR) Team, Joshua Kimano, Julius Oyugi, Erastus Irungu, Jemima Nyakio, Roselyne Malogo, Rose Mahira, Gaudensia Mutua, Lydia Atambo, Borna Nyaoke, Jacquelyn Nyange, Judith Omungo, Timothy Kotikot, Mary W Gichuho, Hilda Ogutu, Rose Ndambuki, Emmanuel Museve, Hannah Nduta Gakure, Dorothy Essendi, Elizabeth Mutiska, Brian Onsembe, Matrona Akiso, Simon Ogola, Nelly Wanjiku, Robert Langat, Jackton Indangasi, Naomi Mwakisha, Irene Mwangi, Marion Agwaya, Ruth Chirchir, Richard Alila, Lewa Said, James Wakonyo, Mercy Musanga, Catherine Kamau, Moses Muriuki, Jason Ndalamia, Catherine Ngeli, Laura Lusik, Catia T Perciani, Manmeet Sekhon, Sabrina Hundal, Bashir Farah, Mario A Ostrowski, A Omu Anzala, Lyle R McKinnon, Walter Jaoko, Kelly S MacDonald, Institute of Tropical and Infectious Diseases (UNITID) Group and the Kenyan AIDS Vaccine Initiative–Institute of Clinical Research (KAVI-ICR) Team, Joshua Kimano, Julius Oyugi, Erastus Irungu, Jemima Nyakio, Roselyne Malogo, Rose Mahira, Gaudensia Mutua, Lydia Atambo, Borna Nyaoke, Jacquelyn Nyange, Judith Omungo, Timothy Kotikot, Mary W Gichuho, Hilda Ogutu, Rose Ndambuki, Emmanuel Museve, Hannah Nduta Gakure, Dorothy Essendi, Elizabeth Mutiska, Brian Onsembe, Matrona Akiso, Simon Ogola, Nelly Wanjiku, Robert Langat, Jackton Indangasi, Naomi Mwakisha, Irene Mwangi, Marion Agwaya, Ruth Chirchir, Richard Alila, Lewa Said, James Wakonyo, Mercy Musanga, Catherine Kamau, Moses Muriuki, Jason Ndalamia, Catherine Ngeli, Laura Lusik

Abstract

Background: Attenuated varicella zoster virus (VZV) is a promising vector for recombinant vaccines. Because human immunodeficiencyvirus (HIV) vaccines are believed to require mucosal immunogenicity, we characterized mucosal VZV-specific humoral immunity following VZVOka vaccination.

Methods: Adult Kenyan VZV-seropositive women (n = 44) received a single dose of the live zoster VZVOka vaccine. The anamnestic responses to the virus were followed longitudinally in both plasma and mucosal secretions using an in-house glycoprotein enzyme-linked immunosorbent assay and safety and reactogenicity monitored. VZV seroprevalence and baseline responses to the virus were also characterized in our cohorts (n = 288).

Results: Besides boosting anti-VZV antibody responses systemically, vaccination also boosted anti-VZV immunity in the cervicovaginal mucosa with a 2.9-fold rise in immunoglobulin G (P < .0001) and 1.6-fold rise in immunoglobulin A (IgA) (P = .004) from the time before immunization and 4 weeks postvaccination. Baseline analysis demonstrated high avidity antibodies at the gastrointestinal and genital mucosa of VZV-seropositive women. Measurement of VZV-specific IgA in saliva is a sensitive tool for detecting prior VZV infection.

Conclusions: VZVOka vaccine was safe and immunogenic in VZV-seropositive adult Kenyan women. We provided compelling evidence of VZV ability to induce genital mucosa immunity.

Clinical trials registration: NCT02514018.

Figures

Figure 1.
Figure 1.
Assessment of mucosal varicella zoster virus (VZV)–specific antibody responses in a cohort of VZV-seropositive women. A, Concentration of VZV-specific immunoglobulin G (IgG) in plasma and VZV-specific IgG and immunoglobulin A (IgA) in cervicovaginal secretions (CVS), rectal secretions (RS), and saliva from 44 VZV-seropositive women. B, Avidity index of VZV-specific IgG in plasma and CVS and of IgA in RS prior to vaccination. Graphs show median and interquartile range. Dotted lines show limit of detection (LOD).
Figure 2.
Figure 2.
Systemic varicella zoster virus (VZV)–specific immunoglobulin G (IgG) prior to and after VZV vaccination in a cohort of VZV-seropositive women. A, Vaccination schedule and longitudinal sample collection time points used in this study. B, Concentration of VZV-specific IgG assessed longitudinally in plasma prior to and up to 48 weeks postvaccination. C, Fold change in VZV-specific IgG concentrations in relation to week 0 (baseline). Graphs show median and interquartile range. Time points were compared to week 0 using Wilcoxon signed-rank test, and adjusted for multiple comparisons using step-down procedure. *P < .05; **P < .01; ****P < .0001. Dotted line shows limit of detection (LOD).
Figure 3.
Figure 3.
Mucosal varicella zoster virus (VZV)–specific immunoglobulin G (IgG) and/or immunoglobulin A (IgA) prior to and after VZV vaccination in a cohort of VZV-seropositive women. A, Concentration of VZV-specific IgG in cervicovaginal secretions (CVS) and of VZV-specific IgA in CVS, rectal secretion (RS), and saliva prior to and postvaccination. B, Fold-change in VZV-specific IgG concentration in CVS and of VZV-specific IgA concentration in CVS, RS, and saliva in relation to week 0. Graphs show median and interquartile range. Time points were compared to week 0 (baseline) using Wilcoxon signed-rank test, and adjusted for multiple comparisons using step-down procedure. *P < .05; **P < .01; ***P < .001; ****P < .0001. Dotted lines indicate the respective limit of detection.
Figure 4.
Figure 4.
Correlations between the concentrations of varicella zoster virus (VZV)–specific immunoglobulin G (IgG) in plasma and VZV-specific IgG and immunoglobulin A (IgA) in mucosal secretions. A, Correlations between VZV-specific IgG levels in plasma and cervicovaginal secretion (CVS), and between VZV-specific IgG levels in plasma and VZV-specific IgA in CVS, saliva, and rectal secretions (RS). B, Correlation between the concentration of anti-VZV IgA in CVS and in the other mucosal secretions (saliva and RS) and between anti-VZV IgA and IgG in CVS. Graphs show the Spearman's correlation (rs), degree of freedom (df), and P value.

References

    1. Fairley CK, Miller E. Varicella-zoster virus epidemiology—a changing scene?J Infect Dis 1996; 174:S314–9.
    1. van Besouw NM, Verjans GM, Zuijderwijk JM, Litjens NH, Osterhaus AD, Weimar W. Systemic varicella zoster virus reactive effector memory T-cells impaired in the elderly and in kidney transplant recipients. J Med Virol 2012; 84:2018–25.
    1. Oxman MN. Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence. J Am Osteopath Assoc 2009; 109:S13–7.
    1. Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974; 2:1288–90.
    1. Zhou F, Harpaz R, Jumaan AO, Winston CA, Shefer A. Impact of varicella vaccination on health care utilization. JAMA 2005; 294:797–802.
    1. Shapiro ED, Vazquez M, Esposito D, et al. . Effectiveness of 2 doses of varicella vaccine in children. J Infect Dis 2011; 203:312–5.
    1. Nguyen HQ, Jumaan AO, Seward JF. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med 2005; 352:450–8.
    1. Oxman MN, Levin MJ, Johnson GR, et al. . Shingles Prevention Study Group A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271–84.
    1. Levin MJ, Oxman MN, Zhang JH, et al. . Veterans Affairs Cooperative Studies Program Shingles Prevention Study Investigators Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008; 197:825–35.
    1. Lal H, Cunningham AL, Godeaux O, et al. . ZOE-50 Study Group Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015; 372:2087–96.
    1. Arvin AM, Moffat JF, Sommer M, et al. . Varicella-zoster virus T cell tropism and the pathogenesis of skin infection. Curr Top Microbiol Immunol 2010; 342:189–209.
    1. Gershon AA, Chen J, Gershon MD. A model of lytic, latent, and reactivating varicella-zoster virus infections in isolated enteric neurons. J Infect Dis 2008; 197:S61–5.
    1. Gray WL. Recombinant varicella-zoster virus vaccines as platforms for expression of foreign antigens. Adv Virol 2013; 2013:219439.
    1. Perciani CT, Jaoko W, Walmsley S, et al. . Protocol of a randomised controlled trial characterising the immune responses induced by varicella-zoster virus (VZV) vaccination in healthy Kenyan women: setting the stage for a potential VZV-based HIV vaccine. BMJ Open 2017; 7:e017391.
    1. Hussey HS, Abdullahi LH, Collins JE, Muloiwa R, Hussey GD, Kagina BM. Varicella zoster virus-associated morbidity and mortality in Africa: a systematic review protocol. BMJ Open 2016; 6:e010213.
    1. Muyanja E, Ssemaganda A, Ngauv P, et al. . Immune activation alters cellular and humoral responses to yellow fever 17D vaccine. J Clin Invest 2014; 124:1.
    1. Lalor MK, Floyd S, Gorak-Stolinska P, et al. . BCG vaccination induces different cytokine profiles following infant BCG vaccination in the UK and Malawi. J Infect Dis 2011; 204:1075–85.
    1. Valdez Y, Brown EM, Finlay BB. Influence of the microbiota on vaccine effectiveness. Trends Immunol 2014; 35:526–37.
    1. Perciani CT, Peixoto PS, Dias WO, Kubrusly FS, Tanizaki MM. Improved method to calculate the antibody avidity index. J Clin Lab Anal 2007; 21:201–6.
    1. Mandal BK, Mukherjee PP, Murphy C, Mukherjee R, Naik T. Adult susceptibility to varicella in the tropics is a rural phenomenon due to the lack of previous exposure. J Infect Dis 1998; 178:S52–4.
    1. Maple PA, Rathod P, Smit E, Gray J, Brown D, Boxall EH. Comparison of the performance of the LIAISON VZV-IgG and VIDAS automated enzyme linked fluorescent immunoassays with reference to a VZV-IgG time-resolved fluorescence immunoassay and implications of choice of cut-off for LIAISON assay. J Clin Virol 2009; 44:9–14.
    1. Gleaves CA, Schwarz KA, Campbell MB. Determination of varicella-zoster virus (VZV) immune status with the VIDAS VZV immunoglobulin G automated immunoassay and the VZVScan latex agglutination assay. Clin Diagn Lab Immunol 1996; 3:365–7.
    1. Li S, Chan IS, Matthews H, et al. . Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection. Pediatr Infect Dis J 2002; 21:337–42.
    1. Diaz C, Dentico P, Gonzalez R, et al. . Protocol 049 Study Group Safety, tolerability, and immunogenicity of a two-dose regimen of high-titer varicella vaccine in subjects > or =13 years of age. Vaccine 2006; 24:6875–85.
    1. Gilbert PB, Gabriel EE, Miao X, et al. . Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve. J Infect Dis 2014; 210:1573–81.
    1. Li Q, Zeng M, Duan L, et al. . Live simian immunodeficiency virus vaccine correlate of protection: local antibody production and concentration on the path of virus entry. J Immunol 2014; 193:3113–25.
    1. Smith AJ, Wietgrefe SW, Shang L, et al. . Live simian immunodeficiency virus vaccine correlate of protection: immune complex-inhibitory Fc receptor interactions that reduce target cell availability. J Immunol 2014; 193:3126–33.
    1. Shang L, Smith AJ, Reilly CS, et al. . Vaccine-modified NF-kB and GR signaling in cervicovaginal epithelium correlates with protection. Mucosal Immunol 2018; 11:512–22.
    1. Adnan S, Reeves RK, Gillis J, et al. . Persistent low-level replication of SIVΔnef drives maturation of antibody and CD8 T cell responses to induce protective immunity against vaginal SIV infection. PLoS Pathog 2016; 12:e1006104.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅